Consensus Novartis AG

Equities

NOVN

CH0012005267

Market Closed - Swiss Exchange Other stock markets 11:30:41 2024-05-31 am EDT			5-day change	1st Jan Change
93.17 ^CHF	+2.13%		+1.56%	+9.78%

May. 31	NOVARTIS AG : UBS reiterates its Buy rating	ZD
May. 31	European Equities Close Higher in Friday Trading; Flash Euro Area Inflation Rises More Than Expected	MT

Evolution of the average Target Price on Novartis AG

Price target over the last 5 years

History of analyst recommendation changes

34565d1d32caa1b5be.0aQ9xBvuyp2w4OWKzZngxOe6bf3dYnb4MR49wEXe1KA.q-ZLvi_fuvLxgb_MtPrXm77VVLu3JE-qfE9LjhKqv-vn53HybLb73IeJkg~57e0ad78ff62acfb91bf7663be23df26

Analyst Recommendations on Novartis AG

NOVARTIS AG : UBS reiterates its Buy rating	May. 31	ZD
NOVARTIS AG : Jefferies remains its Buy rating	May. 31	ZD
Goldman Sachs Starts Novartis With Buy Rating, $120 Price Target	May. 30	MT
NOVARTIS AG : From Sell to buy Rating by Goldman Sachs	May. 30	ZD
NOVARTIS AG : Deutsche Bank remains its Buy rating	May. 24	ZD
Berenberg Raises Price Target on Novartis to CHF77 From CHF74, Maintains Hold Rating	May. 23	MT
NOVARTIS AG : Berenberg remains Neutral	May. 23	ZD
NOVARTIS AG : UBS maintains a Buy rating	May. 06	ZD
NOVARTIS AG : Receives a Buy rating from Jefferies	Apr. 26	ZD
BMO Capital Adjusts Price Target on Novartis to $116 From $114, Maintains Market Perform Rating	Apr. 24	MT
NOVARTIS AG : UBS reaffirms its Buy rating	Apr. 24	ZD
NOVARTIS AG : Deutsche Bank gives a Buy rating	Apr. 24	ZD
NOVARTIS AG : JP Morgan remains Neutral	Apr. 24	ZD
NOVARTIS : 2024 has started on a strong note; guidance upgraded	Apr. 23
NOVARTIS AG : JP Morgan gives a Neutral rating	Apr. 23	ZD
NOVARTIS AG : Barclays keeps a Sell rating	Apr. 23	ZD
NOVARTIS : Oddo BHF confirms its recommendation on the share	Apr. 23	CF
NOVARTIS AG : UBS remains its Buy rating	Apr. 23	ZD
NOVARTIS AG : Gets a Buy rating from Jefferies	Apr. 23	ZD
Novartis Raises Guidance on Profit, Sales Growth -- Update	Apr. 23	DJ
Novartis Raises Guidance on Profit, Sales Growth	Apr. 23	DJ
NOVARTIS AG : UBS reiterates its Buy rating	Apr. 18	ZD
NOVARTIS AG : Deutsche Bank maintains a Buy rating	Apr. 18	ZD
Trending : Novartis Begins Tender Offer for MorphoSys Shares	Apr. 11	DJ
NOVARTIS : UBS reiterates its recommendation on the stock	Apr. 11	CF

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

103.1 USD

Average target price

108.8 USD

Spread / Average Target

+5.50%

High Price Target

130 USD

Spread / Highest target

+26.08%

Low Price Target

84.2 USD

Spread / Lowest Target

-18.34%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Novartis AG

UBS	Matthew Weston
JEFFERIES	Peter Welford
Goldman Sachs
Berenberg Bank
DEUTSCHE BANK RESEARCH	Emmanuel Papadakis
BERENBERG	Kerry Holford
BMO Capital
alphavalue	Abhishek Raval
BARCLAYS	Emily Field
JPMORGAN	Richard Vosser
DZ BANK	Elmar Kraus
Kepler Capital Markets
Societe Generale
Redburn
Stifel Nicolaus
BNP Paribas
MORGAN STANLEY	Mark Purcell
Barrington Research
Credit Suisse
International Strategy & Investment Group
Morningstar
ODDO BHF
DA Davidson
Zacks Equity Research
Bank of America Securities/Merrill Lynch
BERNSTEIN RESEARCH	Wimal Kapadia
Kepler Cheuvreux
Wolfe Research
AltaCorp Capital
DEUTSCHE BANK	Emmanuel Papadakis
HSBC
Exane BNP Paribas
Bryan, Garnier & Co.
Deutsche Bank Securities
Moody's Investors Service
Dundee
Exane BNP
Bernstein
Argus
Cowen
BRYAN GARNIER	Eric Le Berrigaud
LIBERUM CAPITAL	Graham Doyle
BANK OF AMERICA (BOFA)	Graham Parry

Ratings for Novartis AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar